医薬品リファレンス
Dapagliflozin-saxagliptin
Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for diabetes mellitus.
- 薬効分類: Gastrointestinal Tract
- 効能・効果: diabetes mellitus
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Gastrointestinal Tract
- ATCコード
- A10BD21
- 一般的な剤形
- 錠剤
- 一般的な規格
- 5 mg
- 商品名
- 3
- 国・市場
- 3
何に使われるか
作用のしくみ
Dapagliflozin: Selective sodium-glucose transporter-2 (SGLT2) inhibitor; SGLT-2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion
成人の通常用量（添付文書の要約）
Type 2 Diabetes Mellitus: 1 tablet (ie, 10mg/5mg) PO qDay in AM with or without food
妊娠と授乳
- 妊娠
- Unsafe Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred.
- 授乳
- Unsafe No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.
報告されている副作用
- Diarrhea
- Back Pain
- Upper respiratory tract infection (URI)
- Urinary tract infections
- Dyslipidemia
- Headaches
禁忌
- History of hypersensitivity to dapagliflozin or saxagliptin, including anaphylaxis, angioedema, or exfoliative skin conditions
- Moderate-to-severe renal impairment (eGFR <45 mL/min/1.73 m²), end-stage renal disease, or patients on dialysis
注意が必要な方
- Acute pancreatitis reported; after initiating drug, monitor for signs and symptoms of pancreatitis; if suspected, promptly discontinue dapagliflozin/saxagliptin and initiate appropriate management
- May increase risk for developing heart failure (HF) or exacerbation of existing HR; observe patients for signs and symptoms of HF
- Serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization reported in patients receiving SGLT2 inhibitors, including dapagliflozin; treatment with SGLT2 inhibitors increases risk for urinary tract infections; evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Dapagliflozin-saxagliptinの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
- Food interactions
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Dapagliflozin-saxagliptin used for?
Dapagliflozin-saxagliptin is a medicine in the class gastrointestinal tract. It is used for Diabetes mellitus.
What side effects have been reported with Dapagliflozin-saxagliptin?
Diarrhea, Back Pain, Upper respiratory tract infection (URI), Urinary tract infections, Dyslipidemia, Headaches.
Can Dapagliflozin-saxagliptin be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Dapagliflozin: kidney changes in rat offspring; not recommended in the 2nd and 3rd trimesters. Saxagliptin: limited data, no harm in animals. Stop the combination when pregnancy is detected; insulin is preferred. Breastfeeding: Unsafe. No human milk data for either component; both pass into rat milk. Because of possible serious infant reactions (dapagliflozin and kidney maturation), the US label advises not to breastfeed.
What does Dapagliflozin-saxagliptin interact with?
MediHelp does not list a checked interaction for Dapagliflozin-saxagliptin yet. Always tell your pharmacist about every medicine you take.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
